Telomere length, epidemiology and pathogenesis of severe COVID-19

Eur J Clin Invest. 2020 Oct;50(10):e13376. doi: 10.1111/eci.13376. Epub 2020 Sep 5.

Abstract

In December of 2019, an outbreak of pneumonia of unknown cause was reported in Wuhan, Hubei Province, China. By January 2020 a novel coronavirus ‐ that was named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) ‐ was isolated from patients in Wuhan and was identified as the causative pathogen of the disease, which was named Coronavirus disease of 2019 (COVID‐19). In the middle of March the World Health Organization (WHO) announced COVID‐19 outbreak a pandemic. According to the daily report of the WHO, as of 18 July 2020, COVID‐19 has spread rapidly to infect more than 14000000 people and has caused roughly 597000 deaths globally.

Publication types

  • Editorial

MeSH terms

  • Apoptosis / immunology
  • Betacoronavirus
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Cellular Senescence / immunology
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / metabolism
  • Coronavirus Infections / physiopathology
  • Humans
  • Lymphocytes / immunology*
  • Lymphocytes / metabolism
  • Lymphopenia / immunology*
  • Mitochondria / metabolism
  • NAD / metabolism
  • Pandemics
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / metabolism
  • Pneumonia, Viral / physiopathology
  • Risk Factors
  • Severity of Illness Index
  • Sirtuins / metabolism
  • T-Lymphocytes / immunology
  • Telomere / metabolism*
  • Telomere Homeostasis
  • Telomere Shortening / immunology*

Substances

  • NAD
  • Sirtuins

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2